Zinzino group revenue increased with a total of 20%, compared with the previous year.
Gothenburg, Sweden – Zinzino AB (publ) (ZZ-B.ST), a leading global direct selling company, reports that the revenue in January for Zinzino’s sales markets increased by 20% and amounted to SEK 274.1 (229.2) million.
Faun Pharma’s external sales increased and amounted to SEK 7.1 (4.7) million.
Overall, the Group increased revenues by 20% to SEK 281.2 (233.9) million compared with the previous year.
Revenues were distributed as follows:
Regions, mSEK
26-Jan
25-Jan
Change
The Nordics
27.3
25.9
5%
Central Europe
90.1
69.4
30%
East Europe
29.4
34.2
-14%
South & West Europe
46.6
44.1
6%
The Baltics
10.5
10.4
1%
North America
41.3
21.3
94%
South America
4.0
0.9
344%
Asia-Pacific
23.0
21.5
7%
Africa
1.9
1.5
27%
Zinzino
274.1
229.2
20%
Faun Pharma
7.1
4.7
51%
Zinzino Group
281.2
233.9
20%
Countries in regions:
The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
Central Europe: Austria, Germany, Switzerland
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
The Baltics: Estonia, Latvia, Lithuania
North America: Canada, USA, Mexico
South America: Peru, Colombia
Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea
Africa: South Africa
About Zinzino
Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market.
Zinzino’s scientifically proven nutritional supplements are available in more than